SNG100, a novel topical treatment for moderate atopic dermatitis, in patients aged 6 years or older: A randomised, double-blind, active-controlled trial.

Liat SamuelovAvner ShemerShoshana GreenbergerInbal ZivDoron FriedmanOron Yacoby-ZeeviRoni Dodiuk-GadYuval RamotSari MuradEli Sprecher

Published in: Skin health and disease (2023)

Topical SNG100 is an effective, safe, and well-tolerated innovative treatment for moderate AD. Trial registration number: NCT04615962 (Topical Cream SNG100 for Treatment in Moderate AD Subjects).

Keyphrases

double blind
clinical trial
study protocol
end stage renal disease
chronic kidney disease
open label
atopic dermatitis
randomized controlled trial
physical activity
phase iii
prognostic factors
peritoneal dialysis
combination therapy